Clinical Usefulness of Fused PET/CT Compared with PET Alone or CT Alone in Nasopharyngeal Carcinoma Patients
|
|
- Randolf Ryan
- 5 years ago
- Views:
Transcription
1 Clinical Usefulness of Fused PET/CT Compared with PET Alone or CT Alone in Nasopharyngeal Carcinoma Patients YEN-KUNG CHEN 1, CHEN-TAU SU 2, HUEISCH-JY DING 3, KWAN-HWA CHI 4, JI-AN LIANG 5, YEH-YOU SHEN 1, LIANG-KUNG CHEN 2, CHIA-LU YEH 1, ALFRED C. LIAO 1 and CHIA-HUNG KAO 6 Departments of 1 Nuclear Medicine and PET Center, 2 Medical Imaging and 4 Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan; 3 Department of Radiological Technology, I-Shou University, Kaohsiung, Taiwan; Departments of 5 Radiation Therapy and Oncology and 6 Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan, R.O.C. Abstract. The diagnostic accuracy of fused positron emission tomography/computed tomography (PET/CT) was compared with CT alone and PET alone in the staging and re-staging of nasopharyngeal carcinoma (NPC) patients. Patients and Methods: Eighty-six fluorine-18 2-fluoro-2- deoxy-d-glucose (FDG) PET/CT studies were retrospectively performed in 70 patients with NPC, 20 patients for primary tumor staging and 50 patients for re-staging after treatment. Each lesion was analyzed visually and assigned a score on a 5-point scale. Each study was interpreted in 3 ways: PET images were evaluated in the absence of CT data, CT images in the absence of PET data and fused PET/CT images. The results of these images were correlated with histological findings, as well as long-term radiological and clinical followup (the shortest follow-up period after imaging was 6 months). PET, CT and PET/CT accuracy were compared by a McNemar test. Results: Fused PET/CT correctly characterized the tumor-node-metastasis system stage in 82 out of 86 studies (95.4%; 95% CI: 90.9% to 99.9%). PET alone and CT alone were found to be accurate in 71 out of 86 studies (82.6%; 95% CI: 74.5% to 90.6%) and 63 out of 86 studies (73.3%; 95% CI: 63.9% to 82.6%), respectively. Furthermore, the differences between PET/CT and either PET alone or CT alone were statistically significant (p<0.05). Overall, the study-based analysis of PET/CT for staging NPC demonstrated 48 true-positive, 2 false-negative, 34 true-negative and 2 false-positive studies. The sensitivity, Correspondence to: Chia-Hung Kao, MD, Department of Nuclear Medicine and PET Center, China Medical University Hospital, No. 2, Yuh-Der Road, Taichung 404, Taiwan, R.O.C. Tel: , Ext. 3475, Fax: , d10040@ Key Words: Positron emission tomography, computed tomography, PET/CT, 18 F-fluorodeoxyglucose, nasopharyngeal carcinoma. specificity, accuracy, positive predictive value and negative predictive value of FDG-PET/CT studies for staging NPC were 96%, 94.4%, 95.4%, 96% and 94.4%, respectively. Conclusion: PET/CT is more accurate than PET alone or CT alone for the depiction of NPC. Fused PET/CT is a valuable imaging tool in patients for staging diagnosis of NPC. Nasopharyngeal carcinoma (NPC) is an epithelial malignancy occurring worldwide, with particularly high frequencies in southern China, Hong Kong, Singapore and Taiwan (1, 2). Imaging is vital for staging and treatment. The initiation of a stage-adapted therapy is known to improve patient survival for a variety of malignant tumors (3, 4). Computed tomography (CT) and magnetic resonance imaging mainly provide anatomical information on the extent of the primary site and regional metastases. The lack of functional information frequently limits their value for assessment of disease aggressiveness (5, 6). Furthermore, differentiation of scar or recurrent lesions after radiotherapy may be difficult without additional functional data. Fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) provides functional data on tumor metabolism and has been demonstrated to be of complementary value to morphological imaging studies (7, 8). However, limited anatomic information in FDG-PET images frequently renders the localization of a lesion and its potential infiltration into adjacent organs difficult. Sometimes, it is difficult to differentiate between normal and abnormal FDG uptake without detailed anatomical information. Thus, functional datasets should be read in conjunction with morphological images for maximal diagnostic benefit. Image fusion and side-by-side image evaluation of morphological and functional datasets have been proposed. Dual-modality PET/CT tomographs provide the technical basis for intrinsically aligned functional and /2006 $
2 morphological data sets, and has been shown to be superior to whole-body MRI for staging of malignancy (9). Preliminary studies have reported promising results when malignant diseases in the head and neck were assessed with combined PET/CT (10-12). NPC is one of the few head and neck malignancies prone to neck nodes or distant metastases, regardless of the primary tumor size. Therefore, the primary treatment of NPC is radiotherapy and chemotherapy, which require detailed anatomical and functional images. The aim of this study was to compare the sensitivity, specificity and accuracy of dual-modality PET/CT in staging NPC patients relative to CT alone and PET alone. Patients and Methods Patients. Eighty-six FDG-PET examinations of 70 NPC patients in our PET center, from March 2002 to October 2004, were retrospectively studied. Twenty patients (median age 46.3±15.6; 14 men and 6 women) underwent PET/CT scan for primary tumor staging and another 50 patients (median age 50.7±12.8; 38 men and 12 women) for restaging after treatment. The reasons for the PET/CT studies included staging of recently diagnosed NPC (n=18), detection of an unknown primary tumor (n=2), evaluation of residual disease after radiotherapy (n=33) and detection of clinically suspected distant metastatic disease (n=17). All patients gave informed consent to participate in the study according to the guidelines established by the local ethics committee and the Helsinki Declaration. FDG-PET imaging protocol. All patients were imaged with the PET/CT system (Discovery LS, GE Medical Systems, Waukesha, WI, USA). The patients were required to fast for at least 8 hours before the PET/CT scan; furthermore, patients had to be well hydrated and have avoided strenuous work and exercise for 24 h prior to the scan. Patients were scanned in as many sequential images as necessary to include the entire head, thorax, abdomen and pelvis. On the PET/CT scanner, the PET attenuation correction factors were calculated from the CT images. The CT was performed using a 4 detector-row spiral CT (Light-Speed) scanner. Acquisitions occurred at 5-7 bed positions and had the following parameters: 140 kv, 40 ma, 0.8 s per CT rotation, a pitch of 6, a table speed of 22.5 mm/s, coverage of ,011.5 mm and an acquisition time of s. The CT was performed before the emission acquisition. The CT data were resized from a 512x512 matrix to a 128x128 matrix to match the PET data so that the images could be fused and CT transmission maps generated. The transaxial resolution (full width at half maximum) of the PET/CT was 4.8 mm. After i.v. injection of 370 MBq (10 mci) of FDG, emission images were acquired for 5 min per bed position. The uptake period between the FDG injection and the beginning of the emission scan was 60±10 min (range, 50 to 70). The image datasets were obtained by iterative reconstruction (ordered-subset expectation maximization method). The images were displayed in 3 orthogonal projections and as whole-body maximum-pixelintensity reprojection images for visual interpretation. A workstation (Xeleris, Elegems, Haifa, Israel) was used for image display and analysis. Figure 1. Flowchart of newly diagnosed NPC patients enrolled in this study. Abbreviations: CT, computed tomography; PET, position emission tomography;, negative finding; +, positive finding. Image interpretation. All study findings were retrospectively interpreted jointly by and in consensus with one experienced physician trained in diagnostic radiology and one nuclear medicine physician. They were aware of the patient s clinical history, which was provided by the referring physician, but were unaware of the results of other imaging studies if they had been performed. Initially, only the attenuation-corrected PET images in transaxial, coronal and sagittal planes, and maximum intensity projections were reviewed. The images were analyzed visually and lesions with abnormal FDG uptake were recorded. An abnormal FDG uptake was defined (a) as radiotracer accumulation that was thought to be outside of the normal anatomic structures, such as normal laryngeal muscle activity, (b) as uptake that was higher than background activity in the neck or in the location of the normal anatomic structures and (c) as asymmetric and/or of higher intensity than is normally seen. To determine the readers certainty of their decision for each lesion, a 5-point scale was used: 1, definitively not; 2, unlikely; 3, undecided; 4, likely; or 5, definite. An 18 F-FDG PET result of 4 or 5 was considered positive, while a grade of 1, 2, or 3 was considered negative. The radiologist used the same 5-point scale as was applied to the CT images of PET/CT. Afterward, PET/CT images were made available, and the initial findings (i.e. grading of lesions and anatomic location) were amended if necessary. Data analysis. The PET, CT and PET/CT image results were correlated with the histological, endoscopic, surgical and long-term imaging study findings (contrast material-enhanced CT, MR imaging and ultrasonography) as well as with the clinical follow-up periods (the shortest follow-up period after imaging was 6 months). Lesions that had been detected by PET but which were not biopsied were considered to be true-positive findings if the disease became obvious on a follow-up image study, such as MRI or contrast material-enhanced CT. Abnormal foci seen on PET/CT that were not verified during follow-up were considered falsepositive findings. When no abnormality was seen on PET/CT and when there was no further intervention, the result was considered to be a true-negative, if, by other imaging modalities or by clinical follow-up, no disease was identified within 6 months of the PET/CT examination. A study-based analysis of PET/CT was performed. If more than one lesion was present in the same PET/CT study, at least one lesion with a true-positive PET/CT finding was considered a truepositive study of PET/CT. If any one of the lesions with a negative histological finding, long-term radiological and clinical follow-up result was detected by PET/CT, the PET/CT finding was classified 1472
3 Chen et al: Fused PET/CT in Nasopharyngeal Carcinoma Patients Table I. Accuracy of different imaging procedures for assessing T-N-M stage in newly diagnosed NPC patients. Site TP TN FP FN Sensitivity(%) Specificity(%) PPV(%) NPV(%) Accuracy(%) PET Primary ( ) ( ) Regional node Distant ( ) 66.7( ) ( ) Overall ( ) ( ) CT Primary ( ) ( ) Regional node ( ) ( ) 90.0( ) Distant ( ) 66.7( ) ( ) Overall ( ) ( ) PET/CT Primary ( ) ( ) Regional node Distant ( ) 66.7( ) ( ) Overall ( ) ( ) CT: computed tomography, FN: false-negative, FP: false-positive, NPV: negative predictive value, PET: positron emission tomography, PPV: positive predictive value, TN: true-negative, TP: true-positive. as a false-positive PET/CT study. If any one of the lesions was not detected by PET/CT, the PET/CT finding was classified as a falsenegative study of PET/CT. Any difference of opinion was resolved by consensus. Differences in the assessment of the tumor-node-metastasis system stage between the different imaging procedures (CT alone, PET alone and fused PET/CT) were tested for significance (p value <0.05) by McNemar s test. Sensitivities, specificities, negative predictive values, positive predictive values and accuracies with exact 95% confidence intervals (CIs) to detect malignant primary tumor (T stage), lymph nodes (N stage) and distant metastases (M stage) were calculated. Results Among the 20 newly diagnosed NPC patients, 4 patients were staged as T1, 6 T2, 6 T3 and 4 T4 (Figure 1). Bilateral neck lymph node metastases were detected in 16 out of the 20 NPC patients, unilateral neck lymph node metastases were detected in 3 out of the 20 NPC patients and 1 of the 20 NPC patients had no lymph node metastasis. Distant metastases to the spine were detected in 2 out of the 20 NPC patients (Table I). No biopsy of bilateral neck lymph nodes was performed after weighing the risk and benefits, except for 2 patients with enlarged neck lymph nodes due to an unknown primary tumor (before PET scan and primary tumor biopsy). The T stage was accurately determined in 18 out of 20 untreated NPC patients (90%; 95% CI: 76.9% to 100%) with fused PET/CT. Both PET alone and CT alone correctly assessed the T stage in 15 out of 20 untreated NPC patients (75%; 95% CI: 56% to 94%). Among the 20 primary NPC patients, 15 were both PETpositive and CT-positive, 3 were PET-positive but CTnegative (Figure 2), 3 were PET-negative but CT-positive (Figure 3), and 2 were both PET-negative and CT-negative. The N stage could be differentiated more easily with PET than with the CT scan. PET/CT was found to be accurate in 100% (20/20) patients, where PET alone and CT alone accurately determined regional lymph node involvement in 20 out of 20 patients (100%) and 18 out of 20 patients (90%, 95% CI: 76.9% to 100%), respectively. PET, CT and PET/CT accurately differentiated M0 and M1 disease in 19 out of 20 untreated NPC patients (95%, 95% CI: 85.5% to 100%). A comparison of CT, PET and PET/CT did not reveal a statistically significant difference (p>0.05). For re-staging, 66 imaging studies were performed in 50 patients (Table II); among whom, 12 patients underwent the examination twice, 2 three times and 36 only once. Residual and recurrent primary tumors were found on PET images after radiotherapy and chemotherapy in 8 out of the 66 imaging studies, except one was not found in the CT image. Regional lymph node metastases were found on PET images in 11 out of 66 studies and were confirmed by either biopsy or neck lymph node dissection, expect for 2 retropharyngeal lymph nodes confirmed by follow-up imaging studies. There were involved 2 retropharyngeal lymph nodes, 3 level II neck lymph nodes, 2 level IV neck lymph nodes, 4 supraclavicular lymph nodes and 2 submandibular lymph nodes. Three falsepositives were found in the PET images in high jugular, low jugular and submental lymph nodes due to lymphoid hyperplasia. PET images revealed distant metastases to bones (n=10), lungs (n=7), livers (n=4) and para-aortic lymph nodes (n=2). Residual and recurrent T stage were accurately determined in 66 out of 66 studies (100%) with 1473
4 Figure 2. A 71-year-old woman with recently diagnosed NPC underwent PET/CT scan for staging. The PET/CT was performed by a GE discovery LS PET/CT hybrid imaging scanner. The arrows point to an increased FDG uptake in the left nasopharyx in the transaxial (B) image and increased signal in the same region in MRI (D). CT images of the nasopharynx look normal (A). In addition, a combination of the anatomical (A) and physiological (B) PET/CT images show left nasopharynx lesion with hypermetabolism (C). fused PET/CT imaging studies. PET correctly assessed the residual and recurrent T stage in 64 out of 66 studies (97%, 95% CI: 92.8% to 100%) and CT was accurate in 62 out of 66 studies (93.9%; CI: 88.2% to 99.7%). Regarding the N stage of NPC patients with post-treatment, PET/CT was found to be accurate in 50 out of 50 patients. PET alone and CT alone accurately determined regional lymph node involvement in 63 out of 66 studies (95.5%, 95% CI: 90.4% to 100%) and in 58 out of 66 studies (87.9%, 95% CI: 80% to 95.8%), respectively. PET/CT correctly differentiated M0 and M1 disease in 64 out of 66 post-treatment NPC patients (97%, 95% CI: 92.8% to 100%). Both PET alone and CT alone correctly determined M stage in 60 of out 66 studies (90.9%, 95% CI: 84% to 97.8%). Furthermore, the differences between PET/CT and CT alone were statistically significant (p<0.05). The fused PET/CT images provided significantly more accurate interpretations of overall tumor-node-metastasis system stage than either PET alone or CT alone (Table III). The fused PET/CT correctly characterized the tumor-nodemetastasis system stage in 82 out of 86 studies (95.4%; 95% CI: 90.9% to 99.9%). Side by side PET and CT were found to be accurate in 71 out of 86 studies (82.6%; CI: 74.5% to 90.6%) and 63 out of 86 studies (73.3%; CI: 63.9% to 1474
5 Chen et al: Fused PET/CT in Nasopharyngeal Carcinoma Patients Figure 3. A 49-year-old man with recently diagnosed NPC underwent PET/CT scan for staging. The FDG-PET/CT study was performed by a GE discovery LS PET/CT hybrid imaging scanner. The arrow points to mucosa thickening in the right Rosenmulla fossa in the transaxial (A) image. However, in the FDG-PET image, faint FDG uptake in the right nasopharynx (B) was detected. Table II. Accuracy of different imaging procedures for assessing T-N-M restage in post-treatment NPC patients. Site TP TN FP FN Sensitivity(%) Specificity(%) PPV(%) NPV(%) Accuracy(%) PET Primary ( ) 80.0( ) ( ) Regional node ( ) 78.6( ) ( ) Distant ( ) 77.8( ) ( ) Overall ( ) 75.0( ) ( ) *CT Primary ( ) 94.8( ) 70.0( ) 98.2( ) 93.9( ) Regional node ( ) 89.3( ) 57.1( ) 96.2( ) 87.9( ) Distant ( ) 95.7( ) 88.9( ) 91.7( ) 90.9( ) Overall ( ) 75.7( ) 71.0( ) 80.0( ) 75.8( ) PET/CT Primary Regional node Distant ( ) 91.3( ) ( ) Overall ( ) 93.8( ) ( ) CT: computed tomography, FN: false-negative, FP: false-positive, NPV: negative predictive value, PET: positron emission tomography, PPV: positive predictive value, TN: true-negative, TP: true-positive. *Significant difference (p<0.05) compared with PET/CT. Table III. Overall TNM system assessment of NPC in 86 studies by the different imaging procedures. TP TN FP FN Sensitivity(%) Specificity(%) PPV(%) NPV(%) Accuracy(%) *PET *CT PET/CT ( ) 72.2( ) 81.8( ) 83.9( ) 82.6( ) ( ) 75.7( ) 79.6( ) 66.7( ) 73.3( ) ( ) 94.4( ) 96.0( ) 94.4( ) 95.4( ) CT: computed tomography, FN: false-negative, FP: false-positive, NPV: negative predictive value, PET: positron emission tomography, PPV: positive predictive value, TN: true-negative, TP: true-positive. *Significant difference (p<0.05) compared with PET/CT. 1475
6 82.6%), respectively. Furthermore, the differences between PET/CT and either PET alone or CT alone were statistically significant (p<0.05). Overall, the study-based analysis of FDG-PET/CT for staging NPC demonstrated 48 true-positive, 2 false-negative, 34 true-negative and 2 false-positive results. The sensitivity, specificity, accuracy, positive predictive value and negative predictive value of FDG-PET/CT studies for staging NPC were 96%, 94.4%, 95.4%, 96% and 94.4%, respectively. False-positive FDG-PET/CT results in 2 patients were due to a nodular goiter and a solitary pulmonary nodule (granuloma) with intense FDG uptake. False-negative FDG-PET/CT results in 2 patients were due to the primary tumor showing no definite FDG uptake on the PET image and without definite mucosa change in the nasopharynx on the CT image. Discussion NPC is a radiosensitive head and neck malignancy prone to distant metastases. Induction chemotherapy followed by concurrent chemotherapy has been the preferred therapeutic regimen to treat patients with advanced disease (13). Accurate initial assessment of the primary site of NPC and nodal involvement as well as an evaluation of metastasis are crucial in the staging, treatment planning and prognosis judgement in patients with NPC (14-16). The major indications for FDG-PET are (a) staging of regional lymph node (17); (b) predicting response to chemotherapy or radiotherapy; (c) detecting local recurrence or distant metastasis (6); and (d) detection of unknown primaries in patients with upper neck lymph node metastasis. Primary malignancies of the nasopharynx are often understaged during clinical examination. Five percent of patients with head and neck squamous cell carcinoma who present with metastatic cervical nodes had no identifiable primary site on clinical examination. FDG- PET has been shown to reveal unknown primary tumors in approximately 30-50% of patients with metastatic disease to the lymph nodes in the neck who had no detectable primary tumor during clinical examination (18). However, the tumor size may be exaggerated due to the scatter phenomenon of radiation in FDG-PET images. Also, intense FDG uptake may obscure the uptake by adjacent enlarged lymph nodes, thereby resulting in false-negative results. In this study, of the 20 NPC enrolled, primary NPC without FDG uptake was found in 5 patients, no definite mucosa change of the nasopharynx was found on CT images in 5 patients, an intense FDG uptake without mucosa change in the nasopharynx was observed in 3 patients, mucosa thickening without FDG uptake in the nasopharynx was found in 3 patients and no FDG uptake or mucosa change was found in the nasopharynx in 2 patients. Therefore, a fused PET/CT is likely to result in more accurate tumor staging than PET or CT alone (19). FDG-PET is superior to CT and MRI for detecting cervical lymph nodal metastases (16, 20). However, FDG- PET has poor anatomical resolution and cannot accurately assess lymph node size. Although PET is better suited for assessing metastasis in lymph nodes that appear morphologically normal according to size criteria, CT is more accurate for assessing the level and size of nodes, the number of nodes in conglomerate nodal masses and the presence of extracapsular spread (17, 20). Therefore, fused PET/CT is likely to result in more accurate nodal staging than PET alone or CT alone. In generally, false-positive results may occur with FDG- PET because of infections, physiologically increased uptake in structures such as the tonsils, salivary glands and muscles, uptake in reactive non-neoplastic lymph nodes and, recent surgery, noninfectious inflammation and granulation at the surgical site (21). The major advantage of CT is to help correctly differentiate the physiological uptake that would otherwise be mistaken for tumor on PET alone. Fused images with PET/CT allow for direct correlation between FDG metabolic uptake and anatomic structures, thus reducing false-positive results. Standardized uptake values (SUVs) may be useful in distinguishing between malignant and benign FDG uptake, although there is overlap between them. It is important to evaluate the patient s clinical history and physical findings to distinguish between benign and malignant FDG uptake (16, 20). False-negative results with PET/CT may occur under the following conditions: (a) the patient was scanned too early after completion of chemotherapy or radiation therapy; (b) malignancy was present in structures with a physiologically elevated metabolism; (c) tumor size was below the resolution of the current PET/CT scanner; or (d) the tumor was low in cell density or low metabolic rate of FDG. A delayed view with prolonged emission time may be helpful in detecting tumors (22). CT has the ability to depict abnormal anatomy and abnormal contrast enhancement due to pathological changes. However, CT is limited in the depiction of pathological changes in normal-sized structures, such as lymph nodes or of lesions that do not have good contrast with the surrounding tissue, resulting in a reduced sensitivity. In this study, we did not use contrast medium on the examinees because the use of intravenous contrast material may complicate the analysis by introducing additional attenuation-correction artifacts (17, 20). Our data showed that PET/CT is a valuable imaging tool in patients for initial staging and re-staging of NPC. The falsenegative and false-positive rates may be decreased by fused PET/CT. PET/CT is strongly recommended as a standard 1476
7 Chen et al: Fused PET/CT in Nasopharyngeal Carcinoma Patients clinical imaging modality in the staging of NPC and in the detection of recurrent disease after radiotherapy. It provides valuable information for localizing primary tumors in patients with neck nodal metastases from an unknown primary. References 1 Huang DP: Epidemiology of nasopharyngeal carcinoma. Ear Nose Throat J 69: , Vokes EE, Liebowitz DN and Weichselbaum RR: Nasopharyngeal carcinoma. Lancet 350: , Smythe WR: Treatment of stage I and II non-small-cell lung cancer. Cancer Control 8: , Forastiere A, Koch W, Trotti A and Sidransky D: Head and neck cancer. N Engl J Med 345: , Underhill TE, McGuirt WF and Williams DW III: Advances in imaging head and neck tumors. Curr Opin Otolaryngol Head Neck Surg 8: 91-97, Kao CH, ChangLai SP, Chieng PU, Yen RF and Yen TC: Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-deoxyglucose positron emission tomography and comparison with computed tomography. J Clin Oncol 16: , Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE and Phelps ME: A tabulated summary of the FDG PET literature. J Nucl Med 42: 1S-93S, Tsai MH, Huang WS, Tsai JJ, Chen YK, Changlai SP and Kao CH: Differentiating recurrent or residual nasopharyngeal carcinomas from post-radiotherapy changes with 18-fluoro-2- deoxyglucose positron emission tomography and thallium-201 single photon emission computed tomography in patients with indeterminate computed tomography findings. Anticancer Res 23: , Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J, Dahmen G, Bockisch A, Debatin JF and Ruehm SG: Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 290: , Syed R, Bomanji JB, Nagabhushan N, Hughes S, Kayani I, Groves A, Gacinovic S, Hydes N, Visvikis D, Copland C and Ell PJ: Impact of combined (18) F-FDG PET/CT in head and neck tumours. Br J Cancer 92: , Branstetter BF, Blodgett TM, Zimmer LA, Snyderman CH, Johnson JT, Raman S and Meltzer CC: Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology 235: , Schoder H, Yeung HW, Gonen M, Kraus D and Larson SM: Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 231: 65-72, Hong RL, Ting LL, Ko JY, Hsu MM, Sheen TS, Lou PJ, Wang CC, Chung NN and Lui LT: Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 19: , Yen TC, Chang JT, Ng SH, Chang YC, Chan SC, Lin KJ, Lin WJ, Fu YK and Lin CY: The value of 18 F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx. J Nucl Med 46: , Yen RF, Hong RL, Tzen KY, Pan MH and Chen THH: Wholebody 18 F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma. J Nucl Med 46: , Ng SH, Joseph CT, Chan SC, Ko SF, Wang HM, Liao CT, Chang YC, Lin WJ, Fu YK and Yen TC: Clinical usefulness of 18 F-FDG PET in nasopharyngeal carcinoma patients with questionable MRI findings for recurrence. J Nucl Med 45: , Kao CH, Hsieh JF, Tsai SC, Ho YJ, Yen RF, ChangLai SP and Chieng PU: Comparison of 18 F-2-fluoro-2-deoxyglucose positron emission tomography and computed tomography in detection of cervical lymph node metastases of nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol 109: , Assar OS, Fischbein NJ, Caputo GR, Kaplan MJ, Price DC, Singer MI, Dillon WP and Hawkins RA: Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. Radiology 210: , Pelosi E, Messa C, Sironi S, Picchio M, Landoni C, Bettinardi V,Gianolli L, Del Maschio A, Gilardi MC and Fazio F: Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging 31: , Nishioka T, Shiga T, Shirato H, Tsukamoto E, Tsuchiya K, Kato T, Ohmori K, Yamazaki A, Aoyama H, Hashimoto S, Chang TC and Miyasaka K: Image fusion between 18 FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys 53: , Nakamoto Y, Tatsumi M, Hammoud D, Cohade C, Osman MM and Wahl RL: Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology 234: , Chen YK and Kao CH: Metastatic hepatic lesions are detected better by delayed imaging with prolonged emission time. Clin Nucl Med 30: , Received October 31, 2005 Revised January 9, 2006 Accepted January 23,
Bone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When PET Scans Findings Are Equivocal: A Case Report
Bone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When Scans Findings Are Equivocal: A Case Report Yuk-Wah Tsang 1, Jyh-Gang Leu 2, Yen-Kung Chen 3, Kwan-Hwa Chi 1,4
More informationLos Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010
Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010 Self Assessment Module on Nuclear Medicine and PET/CT Case Review FDG PET/CT IN LYMPHOMA AND MELANOMA Submitted
More informationThe Proper Use of PET/CT in Tumoring Imaging
The Proper Use of PET/CT in Tumoring Imaging Mijin Yun, M.D. Jong Doo Lee, M.D. Department of Radiology / Division of Nuclear Medicine Yonsei University College of Medicine, Severance Hospital E mail :
More informationDr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationManagement of Neck Metastasis from Unknown Primary
Management of Neck Metastasis from Unknown Primary.. Definition Histologic evidence of malignancy in the cervical lymph node (s) with no apparent primary site of original tumour Diagnosis after a thorough
More informationFluorodeoxyglucose Positron Emission Tomography in the Evaluation of Tumors of the Nasopharynx, Paranasal Sinuses, and Nasal Cavity
Fluorodeoxyglucose Positron Emission Tomography in the Evaluation of Tumors of the Nasopharynx, Paranasal Sinuses, and Nasal Cavity Brendan C. Stack, Jr, MD, FACS * Val J. Lowe, MD Robert V. Lane, MD *
More informationHEAD AND NECK SQUAMOUS
ORIGINAL ARTICLE The Role of Positron Emission Tomography and Computed Tomography Fusion in the Management of Early-Stage and Advanced-Stage Primary Head and Neck Squamous Cell Carcinoma Patrick K. Ha,
More informationPET CT for Staging Lung Cancer
PET CT for Staging Lung Cancer Rohit Kochhar Consultant Radiologist Disclosures Neither I nor my immediate family members have financial relationships with commercial organizations that may have a direct
More information1 Introduction. 2 Materials and methods. LI Na 1 LI Yaming 1,* YANG Chunming 2 LI Xuena 1 YIN Yafu 1 ZHOU Jiumao 1
Nuclear Science and Techniques 20 (2009) 354 358 18 F-FDG PET/CT in diagnosis of skeletal metastases LI Na 1 LI Yaming 1,* YANG Chunming 2 LI Xuena 1 YIN Yafu 1 ZHOU Jiumao 1 1 Department of Nuclear Medicine,
More informationFDG-PET/CT in Gynaecologic Cancers
Friday, August 31, 2012 Session 6, 9:00-9:30 FDG-PET/CT in Gynaecologic Cancers (Uterine) cervical cancer Endometrial cancer & Uterine sarcomas Ovarian cancer Little mermaid (Edvard Eriksen 1913) honoring
More informationSCIENCE & TECHNOLOGY
Pertanika J. Sci. & Technol. 25 (3): 687-696 (2017) SCIENCE & TECHNOLOGY Journal homepage: http://www.pertanika.upm.edu.my/ The value of 18 F-fluorodeoxyglucose positron emission tomography/ computed tomography
More informationM etastatic disease influences patient management; Whole body PET/CT for initial staging of choroidal melanoma SCIENTIFIC REPORT
1270 SCIENTIFIC REPORT Whole body PET/CT for initial staging of choroidal P T Finger, M Kurli, S Reddy, L B Tena, A C Pavlick... Aim: To investigate the value of whole body positron emission tomography/computed
More informationPositron emission tomography/computer tomography in the evaluation of head and neck cancer treatment
Positron emission tomography/computer tomography in the evaluation of head and neck cancer treatment Severina Šedienė 1, Ilona Kulakienė 1, Viktoras Rudžianskas 2 1 Lithuanian University of Health Sciences,
More informationNew Visions in PET: Surgical Decision Making and PET/CT
New Visions in PET: Surgical Decision Making and PET/CT Stanley J. Goldsmith, MD Director, Nuclear Medicine Professor, Radiology & Medicine New York Presbyterian Hospital- Weill Cornell Medical Center
More informationApplication of 18 F-FDG PET/CT in Nasopharyngeal Carcinoma
Application of 18 F-FDG PET/CT in Nasopharyngeal Carcinoma Yen-Kung Chen 1, Ru-Hwa Cheng 1, Kwan-Hwa Chi 2, Jia-Guang Liang 3, Su-Chen Wang 1, Yeh-You Shen 1, Alfred C. Liao 1, Chen-Tau Su 1 1 Department
More informationWHAT DOES PET IMAGING ADD TO CONVENTIONAL STAGING OF HEAD AND NECK CANCER PATIENTS?
doi:10.1016/j.ijrobp.2006.12.044 Int. J. Radiation Oncology Biol. Phys., Vol. 68, No. 2, pp. 383 387, 2007 Copyright 2007 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/07/$ see front
More informationPET/CT Frequently Asked Questions
PET/CT Frequently Asked Questions General Q: Is FDG PET specific for cancer? A: No, it is a marker of metabolism. In general, any disease that causes increased metabolism can result in increased FDG uptake
More informationAn Introduction to PET Imaging in Oncology
January 2002 An Introduction to PET Imaging in Oncology Janet McLaren, Harvard Medical School Year III Basics of PET Principle of Physiologic Imaging: Allows in vivo visualization of structures by their
More informationROLE OF PET-CT SCAN IN LOCALLY ADVANCED HEAD & NECK CANCER: A Prospective Study
Official publication of Orofacial Chronicle,India www.jhnps.weebly.com ORIGINAL ARTICLE ROLE OF PET-CT SCAN IN LOCALLY ADVANCED HEAD & NECK CANCER: A Prospective Study ABSTRACT: Akheel Mohammad 1, Anuj
More informationThe Use of PET Scanning in Urologic Oncology
The Use of PET Scanning in Urologic Oncology Dr Nicholas C. Buchan Uro-oncology Fellow 1 2 Aims To understand the basic concepts underlying PET scanning. Understand the emerging role of PET Scanning for
More informationResearch Article Prevalence of Clinically Significant Extraosseous Findings on Unenhanced CT Portions of 18 F-Fluoride PET/CT Bone Scans
The Scientific World Journal Volume 2012, Article ID 979867, 5 pages doi:10.1100/2012/979867 The cientificworldjournal Research Article Prevalence of Clinically Significant Extraosseous Findings on Unenhanced
More informationColorectal Cancer and FDG PET/CT
Hybrid imaging in colorectal & esophageal cancer Emmanuel Deshayes IAEA WorkShop, November 2017 Colorectal Cancer and FDG PET/CT 1 Clinical background Cancer of the colon and rectum is one of the most
More informationPET/CT in lung cancer
PET/CT in lung cancer Andrei Šamarin North Estonia Medical Centre 3 rd Baltic Congress of Radiology 08.10.2010 Imaging in lung cancer Why do we need PET/CT? CT is routine imaging modality for staging of
More informationImaging in gastric cancer
Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.
More informationAppendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer
Appendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer Locoregional (N stage) disease was redefined in the seventh edition of the AJCC Cancer Staging Manual as any periesophageal lymph
More informationDirect Comparison of 18 F-FDG PET and PET/CT in Patients with Colorectal Carcinoma
Direct Comparison of F-FDG PET and PET/CT in Patients with Colorectal Carcinoma Christian Cohade, MD; Medhat Osman, MD, PhD; Jeffrey Leal, BA; and Richard L. Wahl, MD Division of Nuclear Medicine, Russell
More informationPET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET
Positron Emission Tomography (PET) When calling Anthem (1-800-533-1120) or using the Point of Care authorization system for a Health Service Review, the following clinical information may be needed to
More informationTc-Methylene Diphosphonate Planar Skull Bone Scan in Detecting Basal Skull Lesions in Nasopharyngeal Carcinoma
99m Tc-Methylene Diphosphonate Planar Skull one Scan in Detecting asal Skull Lesions in Nasopharyngeal Carcinoma Ming-Che Wu 1, Nan-Tsing Chiu 2, i-fang Lee 2 1 Department of Nuclear Medicine, MacKay Memorial
More informationMolecular Imaging and Cancer
Molecular Imaging and Cancer Cancer causes one in every four deaths in the United States, second only to heart disease. According to the U.S. Department of Health and Human Services, more than 512,000
More informationPET with the glucose analog, 18 F-FDG PET, is increasingly
18 F-FDG PET/CT in Evaluating Non-CNS Pediatric Malignancies Mitsuaki Tatsumi 1, John H. Miller 2, and Richard L. Wahl 1 1 Division of Nuclear Medicine, Department of Radiology, The Johns Hopkins Medical
More informationPositron Emission Tomography in Lung Cancer
May 19, 2003 Positron Emission Tomography in Lung Cancer Andrew Wang, HMS III Patient DD 53 y/o gentleman presented with worsening dyspnea on exertion for the past two months 30 pack-year smoking Hx and
More informationDisclosure. Acknowledgement. What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Rectal cancer imaging. None
What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Zhen Jane Wang, MD Assistant Professor in Residence UC SF Department of Radiology Disclosure None Acknowledgement Hueylan Chern, MD, Department
More informationA New Method for Detecting Urinary Bladder Cancer by Using FDG PET/CT
Technology in Cancer Research and Treatment ISSN 1533-0346 Volume 13, Number 4, August 2014 Adenine Press (2014) A New Method for Detecting Urinary Bladder Cancer by Using FDG PET/CT www.tcrt.org DOI:
More informationEarly detection of prostate cancer (PCa) may feasibly lead
ORIGINAL ARTICLE C-11 Choline PET/CT Imaging for Differentiating Malignant From Benign Prostate Lesions Xin Li, MD,* Qi Liu, MD, PhD,* Muwen Wang, MD, PhD,* Xunbo Jin, MD,* Qingwei Liu, MD, PhD,* Shuzhan
More informationFDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave
FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.
More informationVIII. 9. FDG-PET for Diagnosis of an Advanced Jejunal Adenocarcinoma with Distant Metastases, Compared with Gallium Scintigraphy
CYRIC Annual Report 2003 VIII. 9. FDG-PET for Diagnosis of an Advanced Jejunal Adenocarcinoma with Distant Metastases, Compared with Gallium Scintigraphy Yamaura G., Yoshioka T., Yamaguchi K. *, Fukuda
More informationStaging recurrent ovarian cancer with 18 FDG PET/CT
ONCOLOGY LETTERS 5: 593-597, 2013 Staging recurrent ovarian cancer with FDG PET/CT SANJA DRAGOSAVAC 1, SOPHIE DERCHAIN 2, NELSON M.G. CASERTA 3 and GUSTAVO DE SOUZA 2 1 DIMEN Medicina Nuclear and PET/CT
More informationONCOLOGY LETTERS 10: , 2015
ONCOLOGY LETTERS 10: 749-753, 2015 Inability of PET/CT to identify a primary sinonasal inverted papilloma with squamous cell carcinoma in a patient with a submandibular lymph node metastasis: A case report
More informationROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND. Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London
ROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London CANCER Key facts Estimated 15.2 million new cases per year in 2015 worldwide
More informationPOSITRON EMISSION TOMOGRAPHY (PET)
Status Active Medical and Behavioral Health Policy Section: Radiology Policy Number: V-27 Effective Date: 08/27/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members should
More informationPositron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin s Lymphomas (NHL)
CANCER BIOTHERAPY & RADIOPHARMACEUTICALS Volume 16, Number 4, 2001 Mary Ann Liebert, Inc. Positron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin s Lymphomas (NHL) F. Najjar, R. Hustinx, G.
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationTriage of Limited Versus Extensive Disease on 18 F-FDG PET/CT Scan in Small Cell lung Cancer
Triage of Limited Versus Extensive Disease on F-FDG PET/CT Scan in Small Cell lung Cancer Riaz Saima 1*, Bashir Humayun 1, Niazi Imran Khalid 2 1 Department of Nuclear Medicine, Shaukat Khanum Memorial
More informationNeck Imaging Reporting and Data System: An Atlas of NI-RADS Categories for Head and Neck Cancer
Neck Imaging Reporting and Data System: An Atlas of NI-RADS Categories for Head and Neck Cancer Bethany Cavazuti Patricia Hudgins Tanya Rath Char Branstetter Kristen Baugnon Amanda Corey Ashley Aiken Disclosures
More informationto lymph nodes of the neck
[Chinese Journal of Cancer 28:3, 263-267; March 2009]; 2009 Landes Bioscience Clinical Research Paper 18 F-FDG PET/CT for the detection of primary tumors metastasizing to lymph nodes of the neck Ying-Ying
More informationCase Report Diagnostic Consideration for Sinonasal Wegener s Granulomatosis Clinically Mistaken for Carcinoma
Case Reports in Otolaryngology Volume 2013, Article ID 839451, 4 pages http://dx.doi.org/10.1155/2013/839451 Case Report Diagnostic Consideration for Sinonasal Wegener s Granulomatosis Clinically Mistaken
More informationThe following images were all acquired using a CTI Biograph
Positron Emission Tomography/ Computed Tomography Imaging of Head and Neck Tumors: An Atlas Michael M. Graham, MD, PhD, and Yusuf Menda, MD Department of Radiology, University of Iowa, Iowa City, IA. Address
More informationEuropean Journal of Radiology
European Journal of Radiology 82 (2013) 366 373 Contents lists available at SciVerse ScienceDirect European Journal of Radiology journa l h o me pa ge: www.elsevier.com/locate/ejrad Review Accuracy of
More informationFDG-PET/CT for cancer management
195 REVIEW FDG-PET/CT for cancer management Hideki Otsuka, Naomi Morita, Kyo Yamashita, and Hiromu Nishitani Department of Radiology, Institute of Health Biosciences, The University of Tokushima, Graduate
More informationLymphoma Read with the experts
Lymphoma Read with the experts Marc Seltzer, MD Associate Professor of Radiology Geisel School of Medicine at Dartmouth Director, PET-CT Course American College of Radiology Learning Objectives Recognize
More informationRadiological staging of lung cancer. Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh
Radiological staging of lung cancer Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh Bronchogenic Carcinoma Accounts for 14% of new cancer diagnoses in 2012. Estimated to kill ~150,000
More informationHemorrhoids: A Possible Cause of High FDG Uptake in the Rectum
Hemorrhoids: A Possible Cause of High FDG Uptake in the Rectum Yu-Yu Lu, Wan-Yu Lin Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung, Taiwan A 52-year-old man underwent 18 F-FDG
More informationLYMPHATIC DRAINAGE IN THE HEAD & NECK
LYMPHATIC DRAINAGE IN THE HEAD & NECK Like other parts of the body, the head and neck contains lymph nodes (commonly called glands). Which form part of the overall Lymphatic Drainage system of the body.
More informationRecommendations for cross-sectional imaging in cancer management, Second edition
www.rcr.ac.uk Recommendations for cross-sectional imaging in cancer management, Second edition Carcinoma of unknown primary origin (CUP) Faculty of Clinical Radiology www.rcr.ac.uk Contents Carcinoma of
More informationFDG-PET Findings in an Ovarian Endometrioma: A Case Report
FDG-PET Findings in an Ovarian Endometrioma: A Case Report Jia-Huei Lin 1, Victor Chit-kheng Kok 2, Jian-Chiou Su 3 1 Department of Nuclear medicine, Kuang Tien General Hospital, Sha-Lu, Taichung, Taiwan
More informationC ancer cells require a great deal of sugar (glucose) for. PET/CT imaging: detection of choroidal melanoma SCIENTIFIC REPORT
265 SCIENTIFIC REPORT PET/CT imaging: detection of choroidal melanoma S Reddy, M Kurli, L B Tena, P T Finger... Aim: To determine the size of untreated choroidal melanomas resolved by whole body positron
More informationSara Sheikhbahaei 1 Mehdi Taghipour 1 Rubina Ahmad 1 Carole Fakhry 2,3 Ana P. Kiess 4 Christine H. Chung 5 Rathan M. Subramaniam 1,2,5,6
Nuclear Medicine and Molecular Imaging Original Research Nuclear Medicine and Molecular Imaging Original Research Sara Sheikhbahaei 1 Mehdi Taghipour 1 Rubina Ahmad 1 Carole Fakhry 2,3 Ana P. Kiess 4 Christine
More informationPatterns and Prevalence of Misregistration in 18 F-FDG PET/CT
Egyptian J. Nucl. Med., Vol 2, No. 2, Dec. 2009 55 ONCOLOGY, Original Article Patterns and Prevalence of Misregistration in 18 F-FDG PET/CT Farghaly HR,* Muzaffar R,** Bohle RJ,** Nguyen NC,** Osman MM,**
More informationPET/CT in Gynaecological Cancers. Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp
PET/CT in Gynaecological Cancers Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp Cervix cancer Outline of this talk Initial staging Treatment monitoring/guidance
More informationResearch Article The Advantage of PET and CT Integration in Examination of Lung Tumors
Hindawi Publishing Corporation International Journal of Biomedical Imaging Volume 2007, Article ID 17131, 5 pages doi:10.1155/2007/17131 Research Article The Advantage of PET and CT Integration in Examination
More informationShort summary of published results of PET with fluoromethylcholine (18F) in prostate cancer
Short summary of published results of PET with fluoromethylcholine (18F) in prostate cancer JN TALBOT and all the team of Service de Médecine Nucléaire Hôpital Tenon et Université Pierre et Marie Curie,
More informationRegular PET Scanning Without CT. Christian Cohade and Richard L. Wahl
Applications of Positron Emission Tomography/Computed Tomography Image Fusion in Clinical Positron Emission Tomography Clinical Use, Interpretation Methods, Diagnostic Improvements Christian Cohade and
More informationComparison of 18 FDG PET/PET-CT and bone scintigraphy for detecting bone metastases in patients with nasopharyngeal cancer: a meta-analysis
/, 2017, Vol. 8, (No. 35), pp: 59740-59747 Comparison of FDG PET/PET-CT and bone scintigraphy for detecting bone metastases in patients with nasopharyngeal cancer: a meta-analysis Chuanhui Xu 1,*, Ruiming
More informationCURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER
CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER Jean-Pascal Machiels Department of medical oncology Institut I Roi Albert II Cliniques universitaires Saint-Luc Université catholique de Louvain, Brussels,
More informationUtility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC)
Utility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC) Poster No.: C-1360 Congress: ECR 2015 Type: Scientific Exhibit Authors:
More informationComparative evaluation of oral cancer staging using PET-CT vs. CECT
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 5 (2015) pp. 1168-1175 http://www.ijcmas.com Original Research Article Comparative evaluation of oral
More informationPET-MRI in malignant bone tumours. Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany
PET-MRI in malignant bone tumours Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany Content From PET to PET/MRI General considerations Bone metastases Primary bone tumours
More informationCase Report PET/CT Imaging in Oncology: Exceptions That Prove the Rule
Case Reports in Oncological Medicine Volume 2013, Article ID 865032, 4 pages http://dx.doi.org/10.1155/2013/865032 Case Report PET/CT Imaging in Oncology: Exceptions That Prove the Rule M. Casali, 1 A.
More informationTHE COMPARISON OF THREE DIFFERENT MALIGNACY EVALUATION CRITERIA OF CERVICAL LYMPH NODES IN ORAL CAVITY CANCER USING F-18 FDG PET-CT
Acta Medica Mediterranea, 2015, 31: 183 THE COMPARISON OF THREE DIFFERENT MALIGNACY EVALUATION CRITERIA OF CERVICAL LYMPH NODES IN ORAL CAVITY CANCER USING F-18 FDG PET-CT ERDEM SÜRÜCÜ 1, YUSUF DEMIR 1,
More informationUsefulness of Delayed Scan of FDG PET for the Diagnosis of Lymph Node Metastasis in Non-Small Cell Lung Cancer
Yamanashi Med. J. 31(1), 1 8, 20161 Original article Usefulness of Delayed Scan of FDG PET for the Diagnosis of Lymph Node Metastasis in Non-Small Cell Lung Cancer Satoshi KATO 1), Atsushi NAMBU 2) and
More informationClinical significance of the post-radiotherapy. response in nasopharyngeal cancer. Full Paper. 18 F-fludeoxyglucose positron emission tomography
https:// doi. org/ 10. 1259/ bjr. 20180045 Received: 05 January 2018 Revised: 24 July 2018 Accepted: 09 August 2018 2018 The Authors. Published by the British Institute of Radiology under the terms of
More informationComparison of 201 Tl-chloride SPECT with 99m Tc-MIBI SPECT in the depiction of malignant head and neck tumors
ORIGINAL ARTICLE Annals of Nuclear Medicine Vol. 20, No. 2, 107 114, 2006 Comparison of 201 Tl-chloride SPECT with 99m Tc-MIBI SPECT in the depiction of malignant head and neck tumors Noriaki TOMURA, Osamu
More informationPet Scan And Gynaecological Malignancies: Hospital Sultanah Bahiyah Experience
ORIGINAL ARTICLE Pet Scan And Gynaecological Malignancies: Hospital Sultanah Bahiyah Experience T Shahila, MMED (O&G), M N Rushdan, MMED (O&G) Gynaecological Oncology Unit, Department of Obstetrics & Gynaecology,
More informationDetection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer
Eur Respir J 2007; 29: 995 1002 DOI: 10.1183/09031936.00119106 CopyrightßERS Journals Ltd 2007 Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer W. De Wever*, Y.
More informationCase Reports: Tumor Detection by Diffusion-Weighted MRI and ADC-Mapping with Correlation to PET/CT Results
Case Reports: Tumor Detection by Diffusion-Weighted MRI and ADC-Mapping with Correlation to PET/CT Results Matthias Philipp Lichy, M.D.; Philip Aschoff, M.D.; Christina Pfannenberg, M.D.; Schlemmer Heinz-Peter,
More informationNasopharynx. 1. Introduction. 1.1 General Information and Aetiology
Nasopharynx 1. Introduction 1.1 General Information and Aetiology The nasopharynx is the uppermost, nasal part of the pharynx. It extends from the base of the skull to the upper surface of the soft palate.
More informationDiffuse high-attenuation within mediastinal lymph nodes on non-enhanced CT scan: Usefulness in the prediction of benignancy
Diffuse high-attenuation within mediastinal lymph nodes on non-enhanced CT scan: Usefulness in the prediction of benignancy Poster No.: C-1785 Congress: ECR 2012 Type: Authors: Keywords: DOI: Scientific
More informationImplication of 18 F fluorodeoxyglucose uptake by affected lymph nodes in cases with differentiated thyroid cancer
MOLECULAR AND CLINICAL ONCOLOGY 5: 247-251, 2016 Implication of 18 F fluorodeoxyglucose uptake by affected lymph nodes in cases with differentiated thyroid cancer TAKAAKI FUJII, REINA YAJIMA, HIRONORI
More informationPage: 1 of 29. For this policy, PET scanning is discussed for the following 4 applications in oncology:
Emission Tomography Scanning Page: 1 of 29 Last Review Status/Date: June 2015 Description Positron emission tomography (PET) scans are based on the use of positron-emitting radionuclide tracers coupled
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationBone PET/MRI : Diagnostic yield in bone metastases and malignant primitive bone tumors
Bone PET/MRI : Diagnostic yield in bone metastases and malignant primitive bone tumors Lars Stegger, Benjamin Noto Department of Nuclear Medicine University Hospital Münster, Germany Content From PET to
More informationOncologic Applications of PET Scanning
6.01.26 Oncologic Applications of PET Scanning Section 6.0 Radiology Subsection Effective Date February 15, 2015 Original Policy Date January 26, 2009 Next Review Date December 2015 Description Positron
More informationPET SCANS: THE WHO, WHEN AND WHY & HOW TO GET REIMBURSED
PET SCANS: THE WHO, WHEN AND WHY & HOW TO GET REIMBURSED Cecelia E. Schmalbach, MD, FACS Associate Professor of Surgery Head & Neck Surgery Otolaryngology Residency Program Director No Financial Disclosures
More informationAutomatic detection and classification of nasopharyngeal carcinoma on PET/CT with support vector machine
Title Automatic detection and classification of nasopharyngeal carcinoma on PET/CT with support vector machine Author(s) Wu, B; Khong, PL; Chan, T Citation International Journal Of Computer Assisted Radiology
More informationCancer of Unknown Primary (CUP)
Cancer of Unknown Primary (CUP) Pathways and Guidelines V1.0 London Cancer September 2013 The following pathways and guidelines document has been compiled by the London Cancer CUP technical subgroup and
More informationRole of positron emission mammography (PEM) for assessment of axillary lymph node status in patients with breast cancer
Role of positron emission mammography (PEM) for assessment of axillary lymph node status in patients with breast cancer Poster No.: C-1260 Congress: ECR 2011 Type: Scientific Paper Authors: K. M. Kulkarni,
More informationNuclear Medicine in Thyroid Cancer. Phillip J. Koo, MD Division Chief of Diagnostic Imaging
Nuclear Medicine in Thyroid Cancer Phillip J. Koo, MD Division Chief of Diagnostic Imaging Financial Disclosures Bayer Janssen Learning Objectives To learn the advantages and disadvantages of SPECT/CT
More informationPositron emission tomography scanning is coming to a hospital near you soon!
PROFESSIONAL ISSUES Positron emission tomography scanning is coming to a hospital near you soon! Humayun Bashir, Gregory Shabo and TO Nunan Humayun Bashir MB BS FCPS, Specialist Registrar in Nuclear Medicine
More informationDiagnostic role of fluorodeoxyglucose positron emission tomography computed tomography in prostate cancer
ONCOLOGY LETTERS 7: 2013-2018, 2014 Diagnostic role of fluorodeoxyglucose positron emission tomography computed tomography in prostate cancer YIYAN LIU Nuclear Medicine Service, Department of Radiology,
More informationThe Role of PET / CT in Lung Cancer Staging
July 2004 The Role of PET / CT in Lung Cancer Staging Vlad Vinarsky, Harvard Medical School Year IV Patient AM HPI: 81 yo F p/w hemoptysis x 1 month LLL lesion on CXR, not responsive to Abx 35 pack-year
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationThe Egyptian Journal of Hospital Medicine (October 2017) Vol. 69 (4), Page
The Egyptian Journal of Hospital Medicine (October 2017) Vol. 69 (4), Page 2271-2277 Role of Pet/Ct in Assessment of Post Therapeutic Hepatocellular Carcinoma Omar Hussain Omar, Mohamed Elgharib Abo Elmaaty,
More informationUltrasound-Guided Transcutaneous Needle Biopsy of the Base of the Tongue and Floor of the Mouth From a Submental Approach
TECHNICAL INNOVATION Ultrasound-Guided Transcutaneous Needle Biopsy of the Base of the Tongue and Floor of the Mouth From a Submental Approach Jason M. Wagner, MD, Rachel D. Conrad, MD, Trinitia Y. Cannon,
More informationEvaluation of Lung Cancer Response: Current Practice and Advances
Evaluation of Lung Cancer Response: Current Practice and Advances Jeremy J. Erasmus I have no financial relationships, arrangements or affiliations and this presentation will not include discussion of
More informationImaging Decisions Start Here SM
Owing to its high resolution and wide anatomic coverage, dynamic first-pass perfusion 320-detector-row CT outperforms PET/CT for distinguishing benign from malignant lung nodules, researchers from Japan
More informationESMO Preceptorship Program Head & Neck Cancer NPC: Epidemiology, diagnosis and work-up
ESMO Preceptorship Program Head & Neck Cancer NPC: Epidemiology, diagnosis and work-up Dr. John Woo Consultant, ENT Department, PWH Honorary Clinical Professor, Department of Otorhinolaryngology, H&N Surgery
More informationPitfalls in Oncologic Diagnosis with PET CT. Nononcologic Hypermetabolic Findings
Pitfalls in Oncologic Diagnosis with PET CT. Nononcologic Hypermetabolic Findings Poster No.: C-1359 Congress: ECR 2012 Type: Educational Exhibit Authors: J. Rossi 1, C. A. Mariluis 1, E. Delgado 1, R.
More informationCARCINOMA OF UNKNOWN PRIMARY IN THE HEAD AND NECK: COMPARISON BETWEEN POSITRON EMISSION TOMOGRAPHY (PET) AND PET/CT
ORIGINAL ARTICLE CARCINOMA OF UNKNOWN PRIMARY IN THE HEAD AND NECK: COMPARISON BETWEEN POSITRON EMISSION TOMOGRAPHY (PET) AND PET/CT Florian Keller, DDS, 1 Georgios Psychogios, MD, PhD, 1 Rainer Linke,
More informationF-2-fluoro-2-deoxyglucose uptake in or adjacent to blood vessel walls
15 REVIEW 18 F-2-fluoro-2-deoxyglucose uptake in or adjacent to blood vessel walls Yoichi Otomi 1, Hideki Otsuka 2, Kaori Terazawa 1, Hayato Nose 1,3, Michiko Kubo 1, Kazuhide Yoneda 1, Kaoru Kitsukawa
More information